Compound
resveratrol
A stilbenol that is stilbene in which the phenyl groups are substituted at positions 3, 5, and 4' by hydroxy groups.
Studied for
13 endpoints, 13 findings, from 8 papers — 5 of them found no effect.
- C-reactive protein concentrationno detected effectGrade A, Well established. Replicated human trial evidence, consistent direction.
- Fasting blood glucoseno detected effectGrade A, Well established. Replicated human trial evidence, consistent direction.
- Fat masslowersGrade A, Well established. Replicated human trial evidence, consistent direction.
- HDL cholesterolno detected effectGrade A, Well established. Replicated human trial evidence, consistent direction.
- Total cholesterol (TC)no detected effectGrade A, Well established. Replicated human trial evidence, consistent direction.
Structure
Loading the model…
- Class
- Organic compound
- Formula
- C14H12O3
- Mass
- 228.247 g/mol
- Charge
- 0
- InChIKey
- LUKBXSAWLPMMSZ-UHFFFAOYSA-N
- SMILES
- [H]C(=C([H])c1cc(O)cc(O)c1)c1ccc(O)cc1
- Look it up
- ChEBIPubChemBy InChIKey
Identity from ChEBI, geometry from PubChem. Not evidence — none of it carries a grade.
What the evidence says
How to read these marks13 findings across 13 endpoints, from 8 papers, strongest first, 5 of them null.
What moved
8 findings
Decreases fat mass
Well establishedGrade A, Well established. Replicated human trial evidence, consistent direction.Finding“After resveratrol administration, a small but statistically significant reduction in body fat mass was discovered (ES: − 0.3 kg, 95% CI − 0.48 to − 0.12, p = 0.001) (Fig..”
Quoted verbatim from The effect of resveratrol supplementation on obesity indices: a critical umbrella review of interventional meta-analyses.. - Study
- meta-analysis
- Participants
- 1,375
- Dose
- 200 to >1300 mg/day resveratrol across the constituent meta-analyses
- Population
- Pooled across 5 meta-analyses of RCTs of resveratrol supplementation vs non-resveratrol control; mixed clinical and non-clinical adult populations
The effect of resveratrol supplementation on obesity indices: a critical umbrella review of interventional meta-analyses.2025PMID:41317227
Decreases total testosterone
Well establishedGrade A, Well established. Replicated human trial evidence, consistent direction.Finding“The pooled effect estimate indicated that resveratrol significantly reduced the level of testosterone, compared with the placebo (SMD = -0.40; 95% CI [-0.71, -0.10], P = 0.009).”
Quoted verbatim from Efficacy of resveratrol in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials.. - Study
- meta-analysis
- Participants
- 169
- Dose
- 800, 1000 or 1500 mg/day oral resveratrol
- Population
- Women with polycystic ovary syndrome; 3 of 4 pooled RCTs, resveratrol vs placebo
Effect -0.4 standardised mean difference, 95% CI -0.71 to -0.1
Efficacy of resveratrol in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials.2023PMID:37333786
Decreases diastolic blood pressure (setting unspecified)
LikelyGrade B, Likely. Human evidence, limited replication or design limits.Finding“The results illustrated a significant reduction in the DBP by resveratrol after removing these studies (WMD: −3.55 mmHg, 95% CI: −5.18, −1.93; P < 0.0001;.”
Quoted verbatim from Effects of Resveratrol on Metabolic Indicators in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.. - Study
- meta-analysis
- Dose
- 8.1-3000 mg/day resveratrol across the pooled trials
- Population
- Adults with type 2 diabetes; secondary endpoint, pooled after excluding two high-heterogeneity trials, resveratrol vs placebo
Effect -3.55 mean difference, 95% CI -5.18 to -1.93
Effects of Resveratrol on Metabolic Indicators in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.2022PMID:35685602
Increases glutathione peroxidase activity
LikelyGrade B, Likely. Human evidence, limited replication or design limits.Finding“In addition, compared to placebo, Supplementation with resveratrol significantly increased glutathione peroxidase levels (SMD = 0.38, 95%CI(0.03, 0.74), P = 0.04; Level of evidence:low) and catalase levels (SMD = 0.33, 95%CI(0.03, 0.63), P = 0.03; Level of evidence: low).”
Quoted verbatim from The efficacy of resveratrol supplementation on inflammation and oxidative stress in type-2 diabetes mellitus patients: randomized double-blind placebo meta-analysis.. - Study
- meta-analysis
- Population
- patients with type 2 diabetes mellitus (T2DM)
Increases malondialdehyde (circulating)
LikelyGrade B, Likely. Human evidence, limited replication or design limits.Finding“After 12 weeks, MDA levels increased significantly in both groups, with a larger rise in the RES group, resulting in significantly higher MDA levels in the RES group compared to the control at the end of the study.”
Quoted verbatim from Does Resveratrol Impact Oxidative Stress Markers in Patients with Head and Neck Cancer Receiving Home Enteral Nutrition?. - Study
- RCT
- Participants
- 40
- Duration
- 3 months
- Dose
- 400 mg/day liposomal resveratrol via enteral access, in two doses
- Population
- adults with head and neck cancer on home enteral nutrition; open-label, resveratrol plus HEN versus HEN alone
Does Resveratrol Impact Oxidative Stress Markers in Patients with Head and Neck Cancer Receiving Home Enteral Nutrition?2025PMID:39940362
Decreases LDL cholesterol
LikelyGrade B, Likely. Human evidence, limited replication or design limits.Finding“The applied random-effects model showed that resveratrol intake significantly decreased the LDL-C level (Mean difference = −5.69; 95%CI: −11.07, −0.31, p = 0.038, I2 = 64.2%, C).”
Quoted verbatim from The Effect of Resveratrol on Blood Lipid Profile: A Dose-Response Meta-Analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Dose
- 10-3000 mg/day resveratrol across the pooled trials
- Population
- Adults aged 18-85 in 15 placebo-controlled RCTs (16 comparisons), resveratrol vs placebo
Effect -5.69 mean difference, 95% CI -11.07 to -0.31
The Effect of Resveratrol on Blood Lipid Profile: A Dose-Response Meta-Analysis of Randomized Controlled Trials.2022PMID:36145131
Show the remaining 2
Increases catalase activity
LikelyGrade B, Likely. Human evidence, limited replication or design limits.Finding“In addition, compared to placebo, Supplementation with resveratrol significantly increased glutathione peroxidase levels (SMD = 0.38, 95%CI(0.03, 0.74), P = 0.04; Level of evidence:low) and catalase levels (SMD = 0.33, 95%CI(0.03, 0.63), P = 0.03; Level of evidence: low).”
Quoted verbatim from The efficacy of resveratrol supplementation on inflammation and oxidative stress in type-2 diabetes mellitus patients: randomized double-blind placebo meta-analysis.. - Study
- meta-analysis
- Population
- patients with type 2 diabetes mellitus (T2DM)
Increases organism lifespan
SpeculativeGrade F, Speculative. Mechanistic inference, or no evidence found.Finding“Overall, our results indicate that resveratrol acts as a life-extending agent.”
Quoted verbatim from The effect of resveratrol on longevity across species: a meta-analysis.. - Study
- animal · not in humans
- Population
- survival data pooled from 19 published papers across six model species -- yeast, nematodes, mice, fruitflies, Mexican fruitflies and turquoise killifish; abstract only
The effect of resveratrol on longevity across species: a meta-analysis.2012PMID:22718956
What did not
5 findings
Measured, and no effect detected. These are findings, not gaps — a trial that looked and found nothing is the most easily lost result in this field.
No detected effect on fasting blood glucose
Well establishedGrade A, Well established. Replicated human trial evidence, consistent direction.FindingNull result“The results indicated that resveratrol did not improve FBG levels versus placebo (WMD: −3.54 mg/dL, 95% CI: −12.45, 5.38; P=0.44;.”
Quoted verbatim from Effects of Resveratrol on Metabolic Indicators in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.. - Study
- meta-analysis
- Participants
- 1,151
- Dose
- 8.1-3000 mg/day resveratrol across the pooled trials
- Population
- Adults with type 2 diabetes; whole-population pooled estimate across all 19 RCTs, resveratrol vs placebo
Effect -3.54 mean difference, 95% CI -12.45 to 5.38
Effects of Resveratrol on Metabolic Indicators in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.2022PMID:35685602
No detected effect on total cholesterol (TC)
Well establishedGrade A, Well established. Replicated human trial evidence, consistent direction.FindingNull result“The pooled effect estimate revealed no effect of resveratrol on cholesterol (MD = -5.91; 95% CI [-18.54, 6.72], P = 0.36).”
Quoted verbatim from Efficacy of resveratrol in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials.. - Study
- meta-analysis
- Participants
- 108
- Dose
- 1000 or 1500 mg/day oral resveratrol
- Population
- Women with polycystic ovary syndrome; 2 pooled RCTs, resveratrol vs placebo
Effect -5.91 mean difference, 95% CI -18.54 to 6.72
Efficacy of resveratrol in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials.2023PMID:37333786
No detected effect on C-reactive protein concentration
Well establishedGrade A, Well established. Replicated human trial evidence, consistent direction.FindingNull result“The pooled effect estimate revealed no effect of resveratrol on the CRP (MD = 0.00; 95% CI [-1.31, 1.31], P = 1.00).”
Quoted verbatim from Efficacy of resveratrol in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials.. - Study
- meta-analysis
- Participants
- 148
- Dose
- 800, 1000 or 1500 mg/day oral resveratrol
- Population
- Women with polycystic ovary syndrome; 3 pooled RCTs, resveratrol vs placebo
Effect 0 mean difference, 95% CI -1.31 to 1.31
Efficacy of resveratrol in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials.2023PMID:37333786
No detected effect on HDL cholesterol
Well establishedGrade A, Well established. Replicated human trial evidence, consistent direction.FindingNull result“Compared with the placebo, resveratrol did not improve HDL-C levels (WMD: −1.05 mg/dL, 95% CI: −2.44, 0.33; P=0.14;.”
Quoted verbatim from Effects of Resveratrol on Metabolic Indicators in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.. - Study
- meta-analysis
- Participants
- 837
- Dose
- 8.1-3000 mg/day resveratrol across the pooled trials
- Population
- Adults with type 2 diabetes; secondary endpoint, 14 pooled RCTs, resveratrol vs placebo
Effect -1.05 mean difference, 95% CI -2.44 to 0.33
Effects of Resveratrol on Metabolic Indicators in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.2022PMID:35685602
No detected effect on diastolic blood pressure (office/clinic)
SuggestiveGrade C, Suggestive. Weak human evidence, or strong evidence in a mismatched population.FindingNull result“Data analyzed using the multivariate ANOVA model revealed that resveratrol’s effects on systolic and diastolic blood pressure were not statistically significant compared with placebo (Table 3).”
Quoted verbatim from Preliminary, randomized, double-blinded, placebo-controlled cross-over study with resveratrol in hypertensive patients.. - Study
- crossover
- Participants
- 16
- Duration
- 4 weeks
- Dose
- 500 mg twice daily, oral
- Population
- pre-hypertensive and stage-1 hypertensive adults aged 20-60 years, Iran; primary outcome; 2 x 2 crossover, 16 completers analysed
Preliminary, randomized, double-blinded, placebo-controlled cross-over study with resveratrol in hypertensive patients.2025PMID:40854984